Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1(+)CD8(+) T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

PURPOSE: A phase I clinical trial was conducted to assess the safety and feasibility of invariant natural killer T (iNKT) cells combined with PD-1(+)CD8(+) T cells in patients with advanced pancreatic cancer and failing the first-line chemotherapy. PATIENTS AND METHODS: Fifteen eligible patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Cheng, Xiaobo, Jin, Yanling, Xia, Bili, Qin, Ran, Zhang, Wei, Hu, Huiliang, Mao, Xiaoting, Zhou, Liting, Yan, Jia, Zhang, Xiaoyan, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246506/
https://www.ncbi.nlm.nih.gov/pubmed/37377605
http://dx.doi.org/10.1158/2767-9764.CRC-23-0137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246506/
https://www.ncbi.nlm.nih.gov/pubmed/37377605
http://dx.doi.org/10.1158/2767-9764.CRC-23-0137

Ejemplares similares